| First Author | Ma K | Year | 2019 |
| Journal | Biochem Biophys Res Commun | Volume | 513 |
| Issue | 2 | Pages | 306-312 |
| PubMed ID | 30954223 | Mgi Jnum | J:290214 |
| Mgi Id | MGI:6442016 | Doi | 10.1016/j.bbrc.2019.03.159 |
| Citation | Ma K, et al. (2019) Reduced VMAT2 expression exacerbates the hyposmia in the MPTP model of Parkinson's disease. Biochem Biophys Res Commun 513(2):306-312 |
| abstractText | Hyposmia occurs during the prodromal phase of Parkinson's disease (PD), while the underlying mechanisms remain unclear. Discussed are altered dopamine content and impairment of neurogenesis of olfactory bulbs (OB), which has been suggested to be linked to olfactory dysfunction. Given that mouse with reduced vesicular monoamine transporter 2 (VMAT2) expression is now deemed as a relatively new PD animal model simulating motor and nonmotor symptoms, it may provide a new insight into investigating the mechanisms of hyposmia in the context of PD. In this study, we examined the effect of subacute administration of MPTP on mice with a reduced expression of VMAT2, focusing on the histopathological and biochemical alterations, specifically, TH expression level, dopamine content as well as neurogenesis in OB. Interestingly, mice with a reduced VMAT2 expression displayed more obvious olfactory impairment in response to MPTP administration accompanied by markedly decreased dopaminergic interneurons in OB. Furthermore, neurogenesis in OB was also further impaired after MPTP due to reduced VMAT2 expression. We therefore demonstrated that reduced expression of VMAT2 contributed to the impairment of hyposmia, pathologically, the degeneration of extranigral systems and reduced neurogenesis might be the underlying mechanisms. |
